IL255297B - New compounds and methods for immunotherapies containing small molecules that are agonistic adjuvants of the integrin-ligand receptor - Google Patents

New compounds and methods for immunotherapies containing small molecules that are agonistic adjuvants of the integrin-ligand receptor

Info

Publication number
IL255297B
IL255297B IL255297A IL25529717A IL255297B IL 255297 B IL255297 B IL 255297B IL 255297 A IL255297 A IL 255297A IL 25529717 A IL25529717 A IL 25529717A IL 255297 B IL255297 B IL 255297B
Authority
IL
Israel
Prior art keywords
immunotherapies
methods
small molecule
novel compositions
integrin receptor
Prior art date
Application number
IL255297A
Other languages
English (en)
Hebrew (he)
Other versions
IL255297A0 (en
Inventor
G Woodside Darren
Vanderslice Peter
K Marathi Upendra
Original Assignee
7 Hills Interests Llc
Texas Heart Inst
G Woodside Darren
Vanderslice Peter
K Marathi Upendra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 7 Hills Interests Llc, Texas Heart Inst, G Woodside Darren, Vanderslice Peter, K Marathi Upendra filed Critical 7 Hills Interests Llc
Publication of IL255297A0 publication Critical patent/IL255297A0/en
Publication of IL255297B publication Critical patent/IL255297B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C1/00—Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/39—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by a specific adjuvant, e.g. cytokines or CpG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL255297A 2015-04-29 2017-10-27 New compounds and methods for immunotherapies containing small molecules that are agonistic adjuvants of the integrin-ligand receptor IL255297B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562154554P 2015-04-29 2015-04-29
US15/140,711 US10342866B2 (en) 2015-04-29 2016-04-28 Compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants
PCT/US2016/029683 WO2016176400A2 (en) 2015-04-29 2016-04-28 Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants

Publications (2)

Publication Number Publication Date
IL255297A0 IL255297A0 (en) 2017-12-31
IL255297B true IL255297B (en) 2021-10-31

Family

ID=57198770

Family Applications (1)

Application Number Title Priority Date Filing Date
IL255297A IL255297B (en) 2015-04-29 2017-10-27 New compounds and methods for immunotherapies containing small molecules that are agonistic adjuvants of the integrin-ligand receptor

Country Status (10)

Country Link
US (5) US10342866B2 (enExample)
JP (2) JP2018514562A (enExample)
KR (3) KR20240052078A (enExample)
CN (1) CN107820429B (enExample)
AU (1) AU2016254034B2 (enExample)
CA (1) CA2984316A1 (enExample)
IL (1) IL255297B (enExample)
MX (2) MX2017013859A (enExample)
SG (2) SG11201708846XA (enExample)
WO (1) WO2016176400A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240052078A (ko) * 2015-04-29 2024-04-22 7 힐즈 인터레스츠 엘엘씨 소분자 인테그린 수용체-리간드 작용제 보강제를 포함하는 면역치료를 위한 새로운 조성물과 방법
US11311619B2 (en) * 2016-04-28 2022-04-26 7 Hills Pharma Inc. and Texas Heart Institute Integrin activator vaccine compositions
JP7069032B2 (ja) * 2016-03-24 2022-05-17 ミレニアム ファーマシューティカルズ， インコーポレイテッド がん免疫治療における胃腸の免疫関連有害事象の治療方法
WO2018112364A1 (en) * 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Combination therapies for treating melanoma
WO2018112360A1 (en) * 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Combination therapies for treating cancer
WO2021034697A1 (en) * 2019-08-16 2021-02-25 The Regents Of The University Of California Combined cancer therapy involving chemical activation of integrins and targeted cell immunotherapy
US12109263B2 (en) * 2020-09-10 2024-10-08 7 Hills Pharma LLC Integrin agonists or activating compounds and methods for making and using same
KR20240046893A (ko) * 2021-08-10 2024-04-11 텍사스 하트 인스티튜트 아미노아릴-인테그린 작용제 화합물
CA3257474A1 (en) * 2022-05-03 2023-11-09 7 Hills Pharma Inc. NEW LIPID-BASED SMALL MOLECULES INTEGRN LIGAND-RECEPTOR AGONIST SUPPORT COMPOSITIONS, PHARMACEUTICAL INTEGRN AGONIST ADJUVANT COMPOSITIONS PREPARED FROM THESE, AND THEIR PROCESSES FOR MANUFACTURE AND USE

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120258126A1 (en) * 2008-10-02 2012-10-11 Dako Denmark A/S Molecular Vaccines for Infectious Disease
US20130236434A1 (en) * 2010-11-16 2013-09-12 Texas Heart Institute Agonists that enhance binding of integrin-expressing cells to integrin receptors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4505227B2 (ja) * 2001-12-20 2010-07-21 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ １−アルキル−１−アゾニアビシクロ［２．２．２］オクタンカルバメート誘導体およびムスカリンレセプターアンタゴニストとしてのそれらの使用
AU2005249566B2 (en) * 2004-06-04 2010-11-11 Genentech, Inc. Method for treating multiple sclerosis
CN101227885A (zh) * 2005-07-26 2008-07-23 株式会社资生堂 皱纹防止·改善剂
WO2009000406A1 (en) * 2007-06-22 2008-12-31 Bayer Healthcare Ag Use of antibodies against the cd52 antigen for the treatment of neurological disorders, particularly transmissible spongiform encephalopathy and alzheimer's disease
CA2760887A1 (en) * 2009-06-12 2010-12-16 Actelion Pharmaceuticals Ltd Oxazole and thiazole derivatives as alx receptor agonists
US9023876B2 (en) 2010-07-08 2015-05-05 Adhaere Pharmaceuticals, Inc. Compounds and methods for regulating integrins
AU2015217142B2 (en) 2014-02-12 2020-04-09 7 Hills Pharma LLC Compositions and methods to improve the homing and grafting of hematopoetic stem cells
CA2954175C (en) 2014-07-01 2023-07-25 Upendra K. Marathi Compositions and methods to improve adoptive cell therapies
KR20240052078A (ko) * 2015-04-29 2024-04-22 7 힐즈 인터레스츠 엘엘씨 소분자 인테그린 수용체-리간드 작용제 보강제를 포함하는 면역치료를 위한 새로운 조성물과 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120258126A1 (en) * 2008-10-02 2012-10-11 Dako Denmark A/S Molecular Vaccines for Infectious Disease
US20130236434A1 (en) * 2010-11-16 2013-09-12 Texas Heart Institute Agonists that enhance binding of integrin-expressing cells to integrin receptors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANDREW M SCOTT , JEDD D WOLCHOK, LLOYD J OLD, ANTIBODY THERAPY OF CANCER, 22 March 2012 (2012-03-22) *
SWENSON, S., MARKLAND, F., CONAWAY, M.R., THEODORESCU, D., INTEGRIN AGONISTS AS ADJUVANTS IN CHEMOTHERAPY FOR MELANOMA. CLIN CANCER RES. 2008, 14:6193-6197, 1 October 2008 (2008-10-01) *

Also Published As

Publication number Publication date
WO2016176400A2 (en) 2016-11-03
US20220001009A1 (en) 2022-01-06
US12201686B2 (en) 2025-01-21
US10716849B2 (en) 2020-07-21
JP2018514562A (ja) 2018-06-07
WO2016176400A3 (en) 2016-12-08
KR20170136651A (ko) 2017-12-11
JP7244570B2 (ja) 2023-03-22
MX2024002456A (es) 2024-03-08
KR20240052078A (ko) 2024-04-22
KR20240052079A (ko) 2024-04-22
IL255297A0 (en) 2017-12-31
US10709780B2 (en) 2020-07-14
AU2016254034A1 (en) 2017-12-14
US20190343952A1 (en) 2019-11-14
US10709781B2 (en) 2020-07-14
CN107820429B (zh) 2022-08-16
AU2016254034B2 (en) 2021-11-04
MX2017013859A (es) 2018-07-06
JP2021121602A (ja) 2021-08-26
SG10201911607YA (en) 2020-01-30
CN107820429A8 (zh) 2018-06-01
US20160339098A1 (en) 2016-11-24
US20200054743A1 (en) 2020-02-20
US20190351052A1 (en) 2019-11-21
SG11201708846XA (en) 2017-11-29
CN107820429A (zh) 2018-03-20
CA2984316A1 (en) 2016-11-03
US10342866B2 (en) 2019-07-09

Similar Documents

Publication Publication Date Title
IL255297B (en) New compounds and methods for immunotherapies containing small molecules that are agonistic adjuvants of the integrin-ligand receptor
ZA201801750B (en) Farnesoid x receptor agonists and uses thereof
IL248347A0 (en) Compounds and preparations as agonists of toll-like receptor 7
IL248311A0 (en) Compounds and preparations as agonists of toll-like receptor 7
IL256295A (en) Anti-ntb-a antibodies and related compositions and methods
GB201402534D0 (en) Crowd based content delivery
IL247426A0 (en) Pyrazole amide derivatives, preparations containing them and their uses
IL252738A0 (en) Carrier molecule preparations and related methods
SG11201609864UA (en) Novel pyrrolidine compound and application as melanocortin receptor agonist
LT3684813T (lt) Agonistiniai cd40 antikūnai
EP3160961A4 (en) Small molecule agonists of neurotensin receptor 1
PT3217978T (pt) Composições compreendendo benzofuroquinolizina substituída e agonistas adrenérgicos alfa2
PL3209828T3 (pl) Kompozycje włókniste zawierające n-halamine i ich zastosowanie
PT3239177T (pt) Novo anticorpo egfrviii e composição compreendendo o mesmo
EP3102557A4 (en) Improved compositions and methods comprising resveratrol
GB201621528D0 (en) Use of trpv1 agonist
PT3247719T (pt) Proteínas agonistas do receptor met
HK1230173A1 (en) Compounds and compositions as toll-like receptor 7 agonists